肝能滴丸治疗慢性乙型肝炎的临床研究

目的 观察中药肝能滴丸治疗慢性乙型肝炎患者临床抗病毒疗效。方法 选取乙肝病毒主要复制指标HBV-DNA、H＆Ag、HHeAg阳性慢性乙型肝炎患者共84例，开放随机分为肝能滴丸治疗组56例和拉米夫定对照组28例，疗程0．5年；观察两组患者血清船矾卧HBV-DNA的阴转率和肝功能、症状、体征变化情况。结果 治疗组HBV-DNA阴转率为54．0％（27／50例）、HBeAg阴转率30．0％（15／50例）、ALT复常率80．0％（40／50例）；对照组依次为67．9％（19／28例）、21．4％（6／28例）、75．0％（21／28例）；两组比较差异均无显著性（均P〉0．05）。治疗组AST复常率98．0％（48／49例），对照组为48．0％（12／25例），两组比较差异有显著性（P〈0．01）。治疗组症状改善以胁肋胀痛、纳食减少、倦怠乏力、脘闷腹胀、尿黄最为显著，明显优于治疗前（P〈0．05或P〈0．01）。结论 肝能滴丸对慢性乙型肝炎有较好的近期疗效；能有效抑制HBV复制，改善肝功能及症状体征。

Clinical Study on Effect of Ganneng Dripping Pill in Treating Chronic Hepatitis B

ObjectiveTo observe the antiviral efficacy of Ganneng Dripping Pill (GDP) in treating patients with chronic hepatitis B. Methods Eighty-four patients of chronic hepatitis B with positive HBV-DNA, HBsAg, and HBeAg were randomly assigned to 2 groups, the treated group (56 patients) treated with GDP and the control group (28 patients) treated with lamivudine. The therapeutic course for both groups was 6 months. The negative conversion rate of HBeAg and HBV-DNA, changes of liver function, symptoms and physical signs in patients were observed before and after treatment. ResultsIn the treated group, the negative conversion rate of HBV-DNA and HBeAg was 54.0% (27/50) and 30.0% (15/50) respectively, and the ALT normalizing rate was 80.0%(40/50), while those were 67.86%(19/28), 21.8% (6/28) and 75.0% (21/28) respectively in the control group, showing no significant difference between the two groups (all P>0.05). However, the AST normalizing rate was 97.96% (48/49) in the treated group, higher than that in the control group (48.0%, 12/25, P<0.01); and the clinical symptoms, especially the poor appetite, lassitude, gastric distention and yellow urine, were improved more significantly in the treated group than those in the control group (P<0.05 or P<0.01). ConclusionGDP has a favorable short-term effect on chronic hepatitis B, it could effectively inhibit HBV replication and improve the liver function, symptoms and signs in patients.